seizure Clinical Trials

82 recruitingLast updated: July 25, 2026

There are 82 actively recruiting seizure clinical trials across 37 countries. Studies span Not Applicable, Phase 2, Phase 3, Early Phase 1, Phase 1, Phase 4. Top locations include Bethesda, Maryland, United States, Madrid, Spain, Phoenix, Arizona, United States. Updated daily from ClinicalTrials.gov.


seizure Trials at a Glance

82 actively recruiting trials for seizure are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Not Applicable with 22 trials, with the heaviest enrollment activity in Bethesda, Madrid, and Phoenix. Lead sponsors running seizure studies include Mayo Clinic, Rapport Therapeutics Inc., and Supernus Pharmaceuticals, Inc..

Treatments under study

About seizure Clinical Trials

Looking for clinical trials for seizure? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new seizure trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about seizure clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 82 trials

Recruiting
Phase 3

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

EpilepsyFocal EpilepsyFocal Seizure
Rapport Therapeutics Inc.333 enrolled4 locationsNCT07563881
Recruiting
Phase 3

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

EpilepsyFocal EpilepsyFocal Seizure
Rapport Therapeutics Inc.312 enrolled5 locationsNCT07594119
Recruiting
Not Applicable

Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy

Major Depressive DisorderElectroconvulsive TherapyMagnetic Seizure Therapy
The Second Hospital of Anhui Medical University200 enrolled1 locationNCT07473648
Recruiting
Not Applicable

Thalamus Seizure Detection With a Deep Brain Stimulator System

Epilepsy; Seizure
Mayo Clinic5 enrolled1 locationNCT06700356
Recruiting
Phase 3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.160 enrolled138 locationsNCT05667142
Recruiting

Predisposing Factors for Post-stroke Epilepsy

EpilepsyStrokeSeizures+1 more
Norwegian University of Science and Technology30 enrolled1 locationNCT05864547
Recruiting

A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures

Primary Generalized Tonic-Clonic SeizuresPartial-onset Seizures
Eisai Co., Ltd.110 enrolled1 locationNCT06657378
Recruiting
Phase 3

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Stereotypical Prolonged Seizures
UCB Biopharma SRL350 enrolled183 locationsNCT05077904
Recruiting

Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children

Seizures
Children's Hospital of Philadelphia2,500 enrolled1 locationNCT03419260
Recruiting

De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information

EpilepsySeizuresStatus Epilepticus
University of New Mexico20,000 enrolled1 locationNCT05140265
Recruiting

Status Epilepticus Population Study (STEPS)

Epileptic Seizures
University Hospital, Basel, Switzerland1,000 enrolled2 locationsNCT04204863
Recruiting
Phase 2

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Neonatal EncephalopathyNeonatal SeizureSeizure Newborn+1 more
University of California, San Diego133 enrolled5 locationsNCT05610085
Recruiting

Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND

Functional neurological disorderConvulsion, Non-EpilepticFunctional Seizure
University of Alabama at Birmingham1,100 enrolled1 locationNCT06362161
Recruiting
Phase 1

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Focal Seizures
Jazz Pharmaceuticals100 enrolled24 locationsNCT07233239
Recruiting

Investigating Epilepsy: Screening and Evaluation

EpilepsySeizuresEpilepsy, Temporal Lobe+1 more
National Institute of Neurological Disorders and Stroke (NINDS)1,000 enrolled1 locationNCT03478852
Recruiting
Phase 2

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

Focal Onset Seizures
Supernus Pharmaceuticals, Inc.216 enrolled1 locationNCT06798896
Recruiting
Not Applicable

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

seizureEpilepsy
University of Central Florida200 enrolled2 locationsNCT07445074
Recruiting
Phase 3

Levetiracetam for Seizure Prevention After Brain Tumor Surgery

Postoperative Seizures After Brain Tumor Surgery
Beijing Tiantan Hospital558 enrolled1 locationNCT07239115
Recruiting
Phase 3

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Focal Onset Seizures
Xenon Pharmaceuticals Inc.360 enrolled95 locationsNCT05716100
Recruiting
Phase 2

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

EpilepsySeizures, Epileptic
Supernus Pharmaceuticals, Inc.60 enrolled10 locationsNCT05518578